专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4219768A2 COMPOSITIONS, METHODS AND KITS TO DETECT METAPNEUMOVIRUS NUCLEIC ACIDS 审中-实审
公开(公告)号：EP4219768A2
公开(公告)日：2023-08-02
申请号：EP23156298.4
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , HILLIUS, Amber , DOUGLASS, Pamela , KOLK, Daniel
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit comprising at least first and second amplification oligomers, wherein the first amplification oligomer and the second amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159.

2. 发明公开

EP4382619A2 COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS AND AT LEAST ONE OF METAPNEUMOVIRUS AND RHINOVIRUS NUCLEIC ACIDS 审中-实审
公开(公告)号：EP4382619A2
公开(公告)日：2024-06-12
申请号：EP24168848.0
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , DOUGLASS, Pamela , KOLK, Daniel P. , HILLIUS, Amber
IPC分类号： C12Q1/6888
CPC分类号： C12Q1/701 , C12Q2600/1620130101 , C12Q1/6888
摘要： There is disclosed a composition comprising a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein: (A) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer and a second Adenovirus amplification oligomer are configured to amplify an Adenovirus amplicon of at least about 50 nucleotides in length comprising at least one Adenovirus position located in the range of nucleotide positions 52 to 74 of SEQ ID NO:47, nucleotide positions 76 to 99 of SEQ ID NO:47, nucleotide positions 40 to 56 of SEQ ID NO:47, nucleotide positions 65 to 87 of SEQ ID NO:47, nucleotide positions 1 to 18 of SEQ ID NO:47, nucleotide positions 7 to 23 of SEQ ID NO:47, nucleotide positions 28 to 45 of SEQ ID NO:47, nucleotide positions 27 to 45 of SEQ ID NO:47, nucleotide positions 26 to 45 of SEQ ID NO:47, nucleotide positions 139 to 155 of SEQ ID NO:47, nucleotide positions 103 to 123 of SEQ ID NO:47, nucleotide positions 159 to 175 of SEQ ID NO:47, nucleotide positions 83 to 99 of SEQ ID NO:47, and/or nucleotide positions 83 to 98 of SEQ ID NO:47; and (B) for the at least one additional target nucleic acid, (1) a first Metapneumovirus amplification oligomer and a second Metapneumovirus amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least about 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159; and/or (2) a first Rhinovirus amplification oligomer and a second Rhinovirus amplification oligomer are configured to amplify a Rhinovirus amplicon of at least 50 nucleotides in length comprising at least one Rhinovirus position located in the range of nucleotide positions 230 to 556 of SEQ ID NO:120, nucleotide positions 199 to 525 of SEQ ID NO:101, nucleotide positions 80 to 410 of SEQ ID NO:76, nucleotide positions 263 to 303 of SEQ ID NO:120, nucleotide positions 231 to 264 of SEQ ID NO:101, nucleotide positions 106 to 156 of SEQ ID NO:76, nucleotide positions 312 to 346 of SEQ ID NO:120, nucleotide positions 279 to 314 of SEQ ID NO:101, nucleotide positions 455 to 506 of SEQ ID NO:76, nucleotide positions 480 to 533 of SEQ ID NO:120, nucleotide positions 455 to 506 of SEQ ID NO:101, and/or nucleotide positions 338 to 397 of SEQ ID NO:76.

3. 发明公开

EP4219769A2 COMPOSITIONS, METHODS AND KITS TO DETECT RHINOVIRUS NUCLEIC ACID 审中-实审
公开(公告)号：EP4219769A2
公开(公告)日：2023-08-02
申请号：EP23156456.8
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , HILLIUS, Amber , DOUGLASS, Pamela , KOLK, Daniel
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit comprising at least first and second amplification oligomers, wherein the first amplification oligomer and the second amplification oligomer are configured to amplify a Rhinovirus amplicon of at least 50 nucleotides in length comprising at least one Rhinovirus position located in the range of nucleotide positions 230 to 556 of SEQ ID NO: 120, nucleotide positions 199 to 525 of SEQ ID NO:101, nucleotide positions 80 to 410 of SEQ ID NO:76, nucleotide positions 263 to 303 of SEQ ID NO:120, nucleotide positions 231 to 264 of SEQ ID NO:101, nucleotide positions 106 to 156 of SEQ ID NO:76, nucleotide positions 312 to 346 of SEQ ID NO:120, nucleotide positions 279 to 314 of SEQ ID NO:101, nucleotide positions 455 to 506 of SEQ ID NO:76, nucleotide positions 480 to 533 of SEQ ID NO:120, nucleotide positions 455 to 506 of SEQ ID NO:101, and/or nucleotide positions 338 to 397 of SEQ ID NO:76.

4. 发明公开

EP4382619A3 COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS AND AT LEAST ONE OF METAPNEUMOVIRUS AND RHINOVIRUS NUCLEIC ACIDS 审中-实审
公开(公告)号：EP4382619A3
公开(公告)日：2024-08-21
申请号：EP24168848.0
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , DOUGLASS, Pamela , KOLK, Daniel P. , HILLIUS, Amber
IPC分类号： C12Q1/70 , C12Q1/6888
CPC分类号： C12Q1/701 , C12Q2600/1620130101 , C12Q1/6888
摘要： There is disclosed a composition comprising a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein: (A) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer and a second Adenovirus amplification oligomer are configured to amplify an Adenovirus amplicon of at least about 50 nucleotides in length comprising at least one Adenovirus position located in the range of nucleotide positions 52 to 74 of SEQ ID NO:47, nucleotide positions 76 to 99 of SEQ ID NO:47, nucleotide positions 40 to 56 of SEQ ID NO:47, nucleotide positions 65 to 87 of SEQ ID NO:47, nucleotide positions 1 to 18 of SEQ ID NO:47, nucleotide positions 7 to 23 of SEQ ID NO:47, nucleotide positions 28 to 45 of SEQ ID NO:47, nucleotide positions 27 to 45 of SEQ ID NO:47, nucleotide positions 26 to 45 of SEQ ID NO:47, nucleotide positions 139 to 155 of SEQ ID NO:47, nucleotide positions 103 to 123 of SEQ ID NO:47, nucleotide positions 159 to 175 of SEQ ID NO:47, nucleotide positions 83 to 99 of SEQ ID NO:47, and/or nucleotide positions 83 to 98 of SEQ ID NO:47; and (B) for the at least one additional target nucleic acid, (1) a first Metapneumovirus amplification oligomer and a second Metapneumovirus amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least about 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159; and/or (2) a first Rhinovirus amplification oligomer and a second Rhinovirus amplification oligomer are configured to amplify a Rhinovirus amplicon of at least 50 nucleotides in length comprising at least one Rhinovirus position located in the range of nucleotide positions 230 to 556 of SEQ ID NO:120, nucleotide positions 199 to 525 of SEQ ID NO:101, nucleotide positions 80 to 410 of SEQ ID NO:76, nucleotide positions 263 to 303 of SEQ ID NO:120, nucleotide positions 231 to 264 of SEQ ID NO:101, nucleotide positions 106 to 156 of SEQ ID NO:76, nucleotide positions 312 to 346 of SEQ ID NO:120, nucleotide positions 279 to 314 of SEQ ID NO:101, nucleotide positions 455 to 506 of SEQ ID NO:76, nucleotide positions 480 to 533 of SEQ ID NO:120, nucleotide positions 455 to 506 of SEQ ID NO:101, and/or nucleotide positions 338 to 397 of SEQ ID NO:76.

5. 发明公开

EP4219769A3 COMPOSITIONS, METHODS AND KITS TO DETECT RHINOVIRUS NUCLEIC ACID 审中-实审
公开(公告)号：EP4219769A3
公开(公告)日：2023-10-11
申请号：EP23156456.8
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , HILLIUS, Amber , DOUGLASS, Pamela , KOLK, Daniel
IPC分类号： C12Q1/70 , C12Q1/6888
摘要： There is disclosed a composition or kit comprising at least first and second amplification oligomers, wherein the first amplification oligomer and the second amplification oligomer are configured to amplify a Rhinovirus amplicon of at least 50 nucleotides in length comprising at least one Rhinovirus position located in the range of nucleotide positions 230 to 556 of SEQ ID NO: 120, nucleotide positions 199 to 525 of SEQ ID NO:101, nucleotide positions 80 to 410 of SEQ ID NO:76, nucleotide positions 263 to 303 of SEQ ID NO:120, nucleotide positions 231 to 264 of SEQ ID NO:101, nucleotide positions 106 to 156 of SEQ ID NO:76, nucleotide positions 312 to 346 of SEQ ID NO:120, nucleotide positions 279 to 314 of SEQ ID NO:101, nucleotide positions 455 to 506 of SEQ ID NO:76, nucleotide positions 480 to 533 of SEQ ID NO:120, nucleotide positions 455 to 506 of SEQ ID NO:101, and/or nucleotide positions 338 to 397 of SEQ ID NO:76.

6. 发明公开

EP4219768A3 COMPOSITIONS, METHODS AND KITS TO DETECT METAPNEUMOVIRUS NUCLEIC ACIDS 审中-实审
公开(公告)号：EP4219768A3
公开(公告)日：2023-10-11
申请号：EP23156298.4
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , HILLIUS, Amber , DOUGLASS, Pamela , KOLK, Daniel
IPC分类号： C12Q1/70 , C12Q1/6888
摘要： There is disclosed a composition or kit comprising at least first and second amplification oligomers, wherein the first amplification oligomer and the second amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159.

7. 发明公开

EP3601618A1 COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS, METAPNEUMOVIRUS AND/OR RHINOVIRUS NUCLEIC ACIDS 有权
公开(公告)号：EP3601618A1
公开(公告)日：2020-02-05
申请号：EP18717485.9
申请日：2018-03-23
申请人： Gen-Probe Incorporated
发明人： MAJLESSI, Mehrdad R. , SHAH, Ankur , HILLIUS, Amber , DOUGLASS, Pamela , KOLK, Daniel
IPC分类号： C12Q1/70

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式